Furthermore, our model of primary breast cancer can be used as a tool to study the effectiveness of novel mono-therapies and combination therapies that are directed towards cancer that are hyperactive for mTOR and aberrant cancer metabolism. This evidence concerns the gene MTOR and cancer.